Dr. Satoshi Takamatsu graduated from Tohoku University with a PhD. After graduating, he has been consistently involved in contract development and manufacturing of pharmaceuticals (CDMO), pharmaceutical business, and life sciences for over 30 years, working for companies such as Ajinomoto, Fujifilm, and AGC. During his career at Ajinomoto he held various positions in the CDMO field, including research and development, manufacturing, sales, and business management, both domestically and internationally. At Fujifilm, he served as a general manager, leading the expansion of the biopharmaceutical CDMO business, including M&A, and driving pharmaceutical licensing activities. In 2018, he served as the Chief Planning Officer (CPO) at Fujifilm Irvine Scientific, a U.S. company manufacturing cell culture media for biopharmaceuticals, overseeing finance, accounting, human resources, legal affairs, and strategic planning departments and executing post-merger integration (PMI) of acquired companies. In 2020, he joined AGC as the head of the Fine Chemicals division, expanding the CDMO business for small-molecule pharmaceuticals and agrochemicals.
In May 2023, he assumed the position of CEO at ARCALIS, Inc. Leveraging his diverse and global experience in the life sciences and CDMO industry, he aims to lead ARCALIS in establishing a Japanese bio-CDMO company that challenges new modalities and contributes to global health and medical care.

After graduate school, Mr. Fujisawa joined Takeda Pharmaceutical Company as a researcher at the company’s drug discovery center. During his 20-year career at Takeda, he founded Takeda Ventures, the corporate venture arm of Takeda located in Palo Alto, CA, USA. He also served as the global head of Takeda's product licensing and research alliance groups. In 2012, Mr. Fujisawa joined Whiz Partners as Managing Director, where he organized and led the healthcare private equity fund team. In 2021, he was appointed as CIO and Co-COO of Whiz Partners. In 2021, he was appointed as CIO and Co-COO of Whiz Partners. In 2024, he became President and Representative Director, and in 2025, he assumed the role of CEO of the company. He leads Axcelead with experience and foresight in the healthcare field, aiming to build an unprecedented healthcare platform group company.